Product Pipeline

Our priority indications

Therapeutics
Pre-clin
Phase 1
Phase 2
Phase 3
NDA/BLA
Phase
Ryplazim®
Congenital Deficiency
Fezagepras (PBI-4050)
Alström Syndrome
Fezagepras (PBI-4050)
Respiratory Fibrotic Diseases e.g. Idiopathic Pulmonary Fibrosis (IPF)
PBI-4547
Ph 1 suspended to analyze PK data & MOA
GPR84 Antagonist
Undisclosed
Respiratory/GI
Undisclosed
NASH
Undisclosed
Kidney